Business Context and Reporting Period
This Form 10-Q covers Becton, Dickinson and Company (BD) for the quarterly period ended March 31, 2002, and the six months ended on that date. BD is a global medical technology company operating through three primary segments: BD Medical Systems, BD Clinical Laboratory Solutions, and BD Biosciences. The reporting period reflects the adoption of new accounting standards (SFAS 141 and 142) effective October 1, 2001, which eliminated goodwill amortization.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2002 | Six Months Ended Mar 31, 2002 |
|---|---|---|
| Revenues | $1,012,971,000 | $1,957,917,000 |
| Net Income | $129,188,000 | $228,861,000 |
| Diluted EPS | $0.48 | $0.85 |
| Operating Income | $175,927,000 | $317,580,000 |
| Operating Margin | 17.4% | 16.2% |
| Gross Margin | 48.4% | 47.8% |
| Cash from Operations (6mo) | $292,133,000 | N/A |
| Total Debt | $1,322,528,000 | N/A |
| Cash and Equivalents | $180,127,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 7% for the quarter and 8% for the six months compared to the prior year. Growth was driven by the Medical and Clinical Lab segments, though foreign currency translation negatively impacted results by approximately 2%.
- Profitability: Net income rose 13% for the quarter ($129.2M vs. $114.2M) and 51% for the six months ($228.9M vs. $151.1M). The six-month prior year figure included a cumulative effect of an accounting change of $36.8M.
- Special Charges: The company recorded $9.9 million in special charges in the current quarter related to a manufacturing restructuring program in the Medical segment (severance and asset write-downs). No such charges were recorded in the prior year quarter.
- Accounting Changes: The adoption of SFAS 142 eliminated goodwill amortization, providing an approximate 5-cent benefit to diluted EPS for the six-month period.
- Debt and Liquidity: Total debt decreased to $1.3 billion (34.8% of total capital) from 38.9% a year ago. Cash and equivalents increased significantly to $180.1 million from $82.1 million at the prior year-end.
Guidance, Outlook, and Risks
- Divestiture: BD entered a non-binding letter of intent to sell its critical care product line to AorTech International plc for approximately $52 million. The company expects to record a non-cash loss on sale of $25–$30 million in the second half of the fiscal year.
- Restructuring Outlook: Additional special charges of approximately $12 million are anticipated in the third quarter related to the ongoing restructuring program. Net savings from the program are not expected until the third quarter of fiscal 2003.
- Capital Spending: Capital expenditures for fiscal 2002 are expected to be approximately $300 million.
- Tax Rate: The effective tax rate is expected to be about 24% for the full year, excluding special charges.
- Legal Risks: Significant litigation includes antitrust claims filed by Retractable Technologies, Inc., and ongoing product liability class actions regarding needlestick injuries. While the company does not expect a material adverse effect on financial condition, future charges could impact net income.
Investor Verification Checklist
- Verify the final terms and closing date of the critical care product line divestiture to AorTech International plc.
- Monitor the third-quarter financials for the anticipated $12 million in additional restructuring charges.
- Review the impact of foreign currency fluctuations on international revenue growth, which was estimated at a 2% reduction.
- Assess the progress of the manufacturing restructuring program and the timeline for realizing net savings.
- Track developments in the RTI antitrust litigation and the remaining needlestick class action lawsuits.